Investor Overview

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to the millions of patients living with chronic skin conditions.

We are committed to understanding the needs of both patients and physicians and using our insight to identify and develop leading-edge medical dermatology clinical programs.

Stock Quote

Recent News

Toggle Summary Dermira to Present at the Raymond James Life Sciences and MedTech Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Jun. 11, 2019-- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update
QBREXZA™ (glycopyrronium) cloth prescriptions increased more than 50% over fourth quarter 2018 First quarter net product sales of $2.5 million Approximately 80% of commercially insured patients have access to QBREXZA End-of-Phase 2 FDA meeting scheduled following positive lebrikizumab study results
Toggle Summary Dermira to Report First Quarter 2019 Results and Host Conference Call on Tuesday, May 7, 2019
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 30, 2019-- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report
Toggle Summary Dermira to Present at the 18th Annual Needham Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 3, 2019-- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira Announces “Life Unfolds” Direct-to-Consumer Campaign to Highlight QBREXZA™ (glycopyrronium) Cloth
New multichannel consumer campaign will feature QBREXZA patients Campaign to drive consumer awareness of QBREXZA QBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment indicated for people 9 years of age and older with primary axillary hyperhidrosis, also known as

Copyright West LLC. Minimum 15 minutes delayed.